

Benjamin A Steinberg, Mhs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4659867/publications.pdf>

Version: 2024-02-01

130
papers

5,606
citations

117625

34
h-index

82547

72
g-index

140
all docs

140
docs citations

140
times ranked

8161
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. <i>Journal of Cardiac Failure</i> , 2022, 28, 13-20.	1.7	4
2	Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. <i>American Heart Journal</i> , 2022, 243, 127-139.	2.7	8
3	Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices. <i>American Heart Journal</i> , 2022, 244, 116-124.	2.7	3
4	Economics and outcomes of sotalol inpatient dosing approaches in patients with atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 333-342.	1.7	11
5	Clinical strokes in atrial fibrillation: the tip of the iceberg. <i>European Heart Journal</i> , 2022, 43, 2136-2138.	2.2	2
6	Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010304.	4.8	14
7	Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. <i>American Heart Journal</i> , 2022, 248, 42-52.	2.7	6
8	Patient-reported outcomes and costs associated with vascular closure and same-day discharge following atrial fibrillation ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1737-1744.	1.7	3
9	Short-term natural course of esophageal thermal injury after ablation for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1450-1459.	1.7	1
10	Shorter distance between the esophagus and the left atrium is associated with higher rates of esophageal thermal injury after radiofrequency ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1460-1471.	1.7	2
11	Measuring "Symptomatic" Atrial Fibrillation: One View is No View. <i>Heart Rhythm</i> , 2022, , .	0.7	0
12	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561.	2.2	5
13	Association of Wearable Device Use With Pulse Rate and Health Care Use in Adults With Atrial Fibrillation. <i>JAMA Network Open</i> , 2021, 4, e215821.	5.9	24
14	Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. <i>Heart Rhythm</i> , 2021, 18, 709-716.	0.7	24
15	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 153, 58-64.	1.6	5
16	Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 957.	6.1	23
17	Limitations of manufacturer-recommended remote monitoring in the St. Jude Assurity/Endurity battery recall. <i>HeartRhythm Case Reports</i> , 2021, 7, 791-794.	0.4	1
18	Impact of Catheter Ablation on Stroke, Cognitive Decline and Dementia. <i>Arrhythmia and Electrophysiology Review</i> , 2021, 10, 205-210.	2.4	0

#	ARTICLE	IF	CITATIONS
19	Clinical Investigations Bimodal Distribution of Atrial Fibrillation Burden in 3 Distinct Cohorts: What is â€Paroxysmalâ€™™ Atrial Fibrillation?. American Heart Journal, 2021, 244, 149-149.	2.7	0
20	Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121007958.	4.8	20
21	Call me maybe? The right time and place for BPAs in EHRs. European Heart Journal, 2020, 41, 1097-1099.	2.2	2
22	Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. Europace, 2020, 22, 368-374.	1.7	15
23	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	2.7	8
24	Blanking period after radiofrequency ablation for atrial fibrillation guided by ablation lesion maturation based on serial MR imaging. Journal of Cardiovascular Electrophysiology, 2020, 31, 450-456.	1.7	8
25	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. American Heart Journal, 2020, 223, 65-71.	2.7	22
26	Reproducibility of clinical late gadolinium enhancement magnetic resonance imaging in detecting left atrial scar after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2824-2832.	1.7	7
27	Development of a Portable Tool to Identify Patients With Atrial Fibrillation Using Clinical Notes From the Electronic Medical Record. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006516.	2.2	2
28	Social Media Influence Does Not Reflect Scholarly or Clinical Activity in Real Life. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008847.	4.8	4
29	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). American Journal of Cardiology, 2020, 132, 66-71.	1.6	1
30	Patientâ€™reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. Journal of Cardiovascular Electrophysiology, 2020, 31, 3187-3195.	1.7	6
31	Revisiting Rate versus Rhythm Control in Atrial Fibrillation â€™ Timing Matters. New England Journal of Medicine, 2020, 383, 1383-1384.	27.0	18
32	Accuracy of Patient Identification of Electrocardiogram-Verified Atrial Arrhythmias. JAMA Network Open, 2020, 3, e205431.	5.9	3
33	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	3.9	1
34	Impact of Different Electronic Cohort Definitions to Identify Patients With Atrial Fibrillation From the Electronic Medical Record. Journal of the American Heart Association, 2020, 9, e014527.	3.7	19
35	Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. Journal of Arrhythmia, 2020, 36, 84-92.	1.2	7
36	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart, 2020, 106, 358-364.	2.9	16

#	ARTICLE	IF	CITATIONS
37	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	2.2	50
38	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. <i>Heart</i> , 2019, 105, heartjnl-2018-313642.	2.9	22
39	VALIDATION OF AN ELECTRONIC TOOL TO CALCULATE CHA2DS2-VASC SCORES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 496.	2.8	0
40	PATIENT HEALTH STATUS TRAJECTORIES IN HEART FAILURE WITH RECOVERED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 970.	2.8	0
41	Patient-Reported Outcomes in Atrial Fibrillation Research. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 599-605.	3.2	23
42	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAPAF risk scoring systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1440-1447.	1.2	11
43	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1384-1392.	3.2	12
44	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. <i>American Heart Journal</i> , 2019, 213, 81-90.	2.7	10
45	Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBITAF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011205.	3.7	11
46	NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 547.	2.8	0
47	Atrial Fibrillation and Heart Failure: In This Challenge Lies Opportunity. <i>Cardiology Clinics</i> , 2019, 37, xiii.	2.2	0
48	Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure. <i>Cardiology Clinics</i> , 2019, 37, 139-146.	2.2	3
49	Year in Review in Cardiac Electrophysiology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007142.	4.8	2
50	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007612.	4.8	27
51	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBITAF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	143
52	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	2.7	9
53	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. <i>Heart Rhythm</i> , 2018, 15, 651-657.	0.7	102
54	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	6.1	77

#	ARTICLE	IF	CITATIONS
55	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA Cardiology, 2018, 3, 1174.	6.1	111
56	High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 1583-1594.	3.2	81
57	Comparison of 2 Natural Language Processing Methods for Identification of Bleeding Among Critically Ill Patients. JAMA Network Open, 2018, 1, e183451.	5.9	36
58	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). American Journal of Cardiology, 2018, 122, 1677-1683.	1.6	13
59	When Low-Risk Atrial Fibrillation Is Not So Low Risk. JAMA Cardiology, 2018, 3, 558.	6.1	12
60	Year in Review in Cardiac Electrophysiology. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006648.	4.8	3
61	Screening for Atrial Fibrillation With a Wearable Device. JAMA - Journal of the American Medical Association, 2018, 320, 139.	7.4	13
62	Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2017, 119, 1017-1022.	1.6	36
63	Preventing heart failure in atrial fibrillation: In the middle of difficulty lies opportunity. Heart Rhythm, 2017, 14, 799-800.	0.7	0
64	Return on Investment in Implantable Devices. JACC: Heart Failure, 2017, 5, 213-215.	4.1	1
65	Factors associated with nonvitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2017, 189, 40-47.	2.7	53
66	Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends in Cardiovascular Medicine, 2017, 27, 567-572.	4.9	7
67	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology, 2017, 40, 746-751.	1.8	13
68	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Nonvitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 Journal of Cardiology, 2017, 119, 1590-1595.	1.6	33
69	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 319.	6.1	17
70	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. American Journal of Medicine, 2017, 130, 449-456.	1.5	25
71	Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials. Heart Rhythm, 2017, 14, 1839-1848.	0.7	6
72	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161

#	ARTICLE	IF	CITATIONS
73	Implementation of Real-Time Assessment of Patient-Reported Outcomes in a Heart Failure Clinic: A Feasibility Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 813-816.	1.7	33
74	Long-Term Outcomes of Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2487-2489.	2.8	11
75	How I use anticoagulation in atrial fibrillation. <i>Blood</i> , 2016, 128, 2891-2898.	1.4	8
76	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2597-2604.	2.8	401
77	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. <i>JAMA Cardiology</i> , 2016, 1, 282.	6.1	182
78	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2016, 181, 145-152.	2.7	13
79	High-density mapping of the tachycardia circuit in atrioventricular nodal reentrant tachycardia. <i>Heart Rhythm Case Reports</i> , 2016, 2, 451-453.	0.4	6
80	Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital. <i>Europace</i> , 2016, 18, 1117-1118.	1.7	0
81	Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 221-229.	3.2	33
82	Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2015, 33, 177-183.	2.5	67
83	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	2.2	266
84	Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	29
85	Atrioventricular and ventricular-to-ventricular programming in patients with cardiac resynchronization therapy: results from ALTITUDE. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 44, 279-287.	1.3	11
86	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 488-494.	1.6	224
87	Outcomes After Nonemergent Electrical Cardioversion for Atrial Arrhythmias. <i>American Journal of Cardiology</i> , 2015, 115, 1407-1414.	1.6	7
88	Heart rate is associated with progression of atrial fibrillation, independent of rhythm. <i>Heart</i> , 2015, 101, 894-899.	2.9	52
89	Interruption of all anticoagulation is non-inferior to the use of short-term parenteral bridging in patients with atrial fibrillation undergoing invasive procedures. <i>Evidence-Based Medicine</i> , 2015, 20, 200-200.	0.6	1
90	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015, 4, e002031.	3.7	41

#	ARTICLE	IF	CITATIONS
91	MODULES OVER $\tilde{\mathcal{A}}\%$ TALE GROUPOID ALGEBRAS AS \hat{S} SHEAVES. Journal of the Australian Mathematical Society, 2014, 97, 418-429.	0.4	17
92	Refined bleeding estimates in adults starting anticoagulants. BMJ, The, 2014, 349, g4800-g4800.	6.0	1
93	Risk assessment in atrial fibrillation: not all factors are created equal. Europace, 2014, 16, 156-158.	1.7	0
94	Management of Postoperative Atrial Fibrillation and Subsequent Outcomes in Contemporary Patients Undergoing Cardiac Surgery: Insights From the Society of Thoracic Surgeons \langle scp>CAPS \rangle \hat{A} Care Atrial Fibrillation Registry. Clinical Cardiology, 2014, 37, 7-13.	1.8	105
95	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. JACC: Heart Failure, 2014, 2, 623-629.	4.1	72
96	Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation. Heart, 2014, 100, 1871-1877.	2.9	16
97	Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation. Evidence-Based Medicine, 2014, 19, 182-182.	0.6	0
98	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm, 2014, 11, 925-932.	0.7	52
99	Structure \hat{E} function relationships of factor Xa inhibitors: implications for the practicing clinician. Journal of Thrombosis and Thrombolysis, 2014, 37, 234-241.	2.1	7
100	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Circulation, 2014, 129, 2005-2012.	1.6	73
101	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	2.7	120
102	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	1.7	9
103	Comparison of Safety of Sotalol Versus Amiodarone in \hat{A} Patients With Atrial Fibrillation and Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 716-722.	1.6	9
104	Anticoagulation in atrial fibrillation. BMJ, The, 2014, 348, g2116-g2116.	6.0	68
105	Cost Analysis of Periprocedural Imaging in Patients Undergoing Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2014, 114, 266-271.	1.6	5
106	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. American Heart Journal, 2014, 168, 160-167.	2.7	62
107	ASSESSMENT OF STROKE RISK IN ATRIAL FIBRILLATION: PHYSICIAN ESTIMATE VERSUS CHADS2 RISK SCORE: RESULTS FROM ORBIT-AF. Journal of the American College of Cardiology, 2014, 63, A357.	2.8	0
108	Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. Journal of Interventional Cardiac Electrophysiology, 2013, 37, 213-221.	1.3	45

#	ARTICLE	IF	CITATIONS
109	Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2013, 165, 622-629.	2.7	61
110	Left Atrial Remodeling: Shape Before Size?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 760-761.	1.7	5
111	Comparative Effectiveness of Pharmacotherapies for Prevention of Atrial Fibrillation Following Coronary Artery Bypass Surgery. <i>American Journal of Cardiology</i> , 2013, 112, 954-960.	1.6	17
112	Dose-adjusted warfarin: writing the prescription is only the beginning. <i>Journal of Electrocardiology</i> , 2013, 46, 51-53.	0.9	0
113	Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 721-728.	1.6	132
114	Evaluation and Management of the Atrial Fibrillation Patient. <i>Critical Pathways in Cardiology</i> , 2013, 12, 107-115.	0.5	4
115	Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2013, 2, e000535.	3.7	92
116	Treatment Pathways and Quality Improvement for Patients With Acute Myocardial Infarction at a Tertiary Care Center. <i>Critical Pathways in Cardiology</i> , 2012, 11, 77-80.	0.5	2
117	Cardiac conduction system disease after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2012, 164, 664-671.	2.7	43
118	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Circulation</i> , 2012, 126, 65-75.	1.6	681
119	Is Coding for Myocardial Infarction More Accurate Now That Coding Descriptions Have Been Clarified to Distinguish ST-Elevation Myocardial Infarction from Non-ST Elevation Myocardial Infarction?. <i>American Journal of Cardiology</i> , 2008, 102, 513-517.	1.6	28
120	Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. <i>American Heart Journal</i> , 2008, 156, 719-727.	2.7	82
121	An Annual, Prospective, International Study of Outpatients With Cardiovascular Disease or Risk Factors. <i>Critical Pathways in Cardiology</i> , 2007, 6, 72-75.	0.5	2
122	Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. <i>American Heart Journal</i> , 2007, 154, 54-61.	2.7	19
123	Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry). <i>American Journal of Cardiology</i> , 2007, 99, 1212-1215.	1.6	40
124	Medical Therapies and Invasive Treatments for Coronary Artery Disease by Body Mass: The "Obesity Paradox" in the Get With The Guidelines Database. <i>American Journal of Cardiology</i> , 2007, 100, 1331-1335.	1.6	130
125	Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Safety, Tolerability, and Therapeutic Potential. <i>American Journal of Cardiology</i> , 2007, 100, S27-S32.	1.6	24
126	Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2006, 48, 438-445.	2.8	668

#	ARTICLE	IF	CITATIONS
127	Missed Diagnosis of the Diagnosis Codes. <i>Critical Pathways in Cardiology</i> , 2006, 5, 59-63.	0.5	4
128	Are Statins Being Underdosed in Clinical Practice?. <i>Critical Pathways in Cardiology</i> , 2005, 4, 169-173.	0.5	8
129	Magnetocardiogram Recordings in a Nonshielded Environmentâ€™Reproducibility and Ischemia Detection. <i>Annals of Noninvasive Electrocardiology</i> , 2005, 10, 152-160.	1.1	26
130	Safety of Bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. <i>International Journal of Cardiovascular Interventions</i> , 2005, 7, 88-92.	0.5	13